GW Pharmaceuticals PLC- (NASDAQ:GWPH) had its price objective cut by equities research analysts at Cantor Fitzgerald from $211.00 to $193.00 in a research report issued to clients and investors on Sunday. Cantor Fitzgerald’s target price would indicate a potential upside of 54.60% from the company’s current price. Cantor Fitzgerald also issued estimates for GW Pharmaceuticals PLC-‘s FY2019 earnings at ($6.24) EPS.

Several other analysts have also commented on the stock. Morgan Stanley set a $227.00 target price on shares of GW Pharmaceuticals PLC- and gave the company a “buy” rating in a research note on Thursday, October 11th. Stifel Nicolaus initiated coverage on shares of GW Pharmaceuticals PLC- in a research note on Tuesday, August 14th. They set a “buy” rating and a $181.00 target price for the company. BidaskClub raised shares of GW Pharmaceuticals PLC- from a “hold” rating to a “buy” rating in a research note on Saturday, September 22nd. Piper Jaffray Companies reissued an “overweight” rating on shares of GW Pharmaceuticals PLC- in a research note on Monday, November 5th. Finally, Leerink Swann initiated coverage on shares of GW Pharmaceuticals PLC- in a research note on Monday, November 12th. They set an “outperform” rating and a $185.00 target price for the company. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating, eight have given a buy rating and one has issued a strong buy rating to the stock. The company has a consensus rating of “Buy” and an average target price of $185.38.

GWPH stock traded up $2.12 on Friday, hitting $124.84. 432,580 shares of the company’s stock traded hands, compared to its average volume of 447,405. GW Pharmaceuticals PLC- has a 1-year low of $105.12 and a 1-year high of $179.65. The firm has a market cap of $3.77 billion, a PE ratio of -11.82 and a beta of 2.16. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.66 and a quick ratio of 6.34.

GW Pharmaceuticals PLC- (NASDAQ:GWPH) last released its earnings results on Tuesday, November 27th. The biopharmaceutical company reported ($2.76) EPS for the quarter, missing the consensus estimate of ($2.48) by ($0.28). GW Pharmaceuticals PLC- had a negative net margin of 1,574.21% and a negative return on equity of 50.93%. The business had revenue of $2.40 million for the quarter, compared to analyst estimates of $2.62 million. During the same period in the prior year, the company earned ($0.14) earnings per share. The firm’s revenue for the quarter was down 4.0% on a year-over-year basis. As a group, sell-side analysts expect that GW Pharmaceuticals PLC- will post -9.24 earnings per share for the current year.

Several large investors have recently modified their holdings of GWPH. Flagship Harbor Advisors LLC purchased a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter valued at approximately $109,000. Envestnet Asset Management Inc. purchased a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter valued at approximately $119,000. Cowen Prime Services LLC lifted its position in shares of GW Pharmaceuticals PLC- by 708.0% in the 2nd quarter. Cowen Prime Services LLC now owns 1,010 shares of the biopharmaceutical company’s stock valued at $141,000 after acquiring an additional 885 shares in the last quarter. NumerixS Investment Technologies Inc purchased a new stake in shares of GW Pharmaceuticals PLC- in the 2nd quarter valued at approximately $166,000. Finally, BNP Paribas Arbitrage SA lifted its position in shares of GW Pharmaceuticals PLC- by 497.0% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,200 shares of the biopharmaceutical company’s stock valued at $167,000 after acquiring an additional 999 shares in the last quarter. Institutional investors and hedge funds own 69.38% of the company’s stock.

About GW Pharmaceuticals PLC-

GW Pharmaceuticals plc, a biopharmaceutical company, engages in discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. The company operates through three segments: Commercial, Sativex Research and Development, and Pipeline Research and Development.

Featured Article: Why do corrections happen?

Analyst Recommendations for GW Pharmaceuticals PLC- (NASDAQ:GWPH)

Receive News & Ratings for GW Pharmaceuticals PLC- Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC- and related companies with MarketBeat.com's FREE daily email newsletter.